European medical regulators have given the thumbs up to the new AstraZeneca diabetes treatment . The drug, known as Onglyza, is a collab between the UK-based company and US group Bristol-Myers Squibb .
Onglyza (Saxagliptin) will be used to treat diabetes patients who have type 2 diabetes . It is designed to be used alone with diet and exercise, or used with metformin and other diabetes drugs to aid in blood sugar control .
The approval was based on research involving 4,000 diabetes patients and reportedly proved that the drug can significantly reduce blood sugar levels when added to regular diabetes treatments . The drug is one of the first DPP-4 inhibitors to be approved, and is also less likely to cause weight gain.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…